Immunotherapy with anti‐GD2 monoclonal antibody in infants with high‐risk neuroblastoma
- 17 August 2022
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 152 (2) , 259-266
Abstract
Anti‐GD2 monoclonal antibodies (mAb) improve the prognosis of high‐risk neuroblastoma (HR‐NB). Worldwide experience almost exclusively involves toddlers and older patients treated after multimodality or second‐line therapies, that is, many months postdiagnosis. In contrast, at our center, infants received anti‐GD2 mAbs because this immunotherapy started during or immediately after induction chemotherapy. We now report on the feasibility, safety, and long‐term survival in this vulnerable age group. Thirty‐three HR‐NB patients were 2.5× higher (~270 mg/m2/cycle) than 3F8, dinutuximab, and dinutuximab beta (70‐100 mg/m2/cycle). HR‐NB in infants proved to be highly curable.Keywords
Funding Information
- National Cancer Institute (P30 CA008748)
This publication has 30 references indexed in Scilit:
- Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trialThe Lancet Oncology, 2013
- High-dose cyclophosphamide–irinotecan–vincristine for primary refractory neuroblastomaEuropean Journal of Cancer, 2011
- Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapyBMC Cancer, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastomaJournal of Neuro-Oncology, 2009
- Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2009
- Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous systemBone Marrow Transplantation, 2006
- Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology GroupJournal of Clinical Oncology, 2005
- Infants with Stage 4 Neuroblastoma: The Impact of the Chimeric Anti-GD2-Antibody ch14.18 Consolidation TherapyKlinische Padiatrie, 2005
- Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk NeuroblastomaJournal of Clinical Oncology, 2004